BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativa (BIOLOPTIM)

Concrete goals and criteria: The success of this project is based on different objectives:

• Exploration of non-inferiority of dose reduction during adalimumab treatment in real life
• Research into the use of DBS and creation of exta samples for measurement adalimumab levels
• Development of a model and prediction tool to guide physicians at adalimumab
• Development and validation of assays to measure the trailing levels of the new class of biologics and anti-drug titers
• Investigation of association between the new class of biologics levels and the clinical response
• Identify potential clinical and demographic markers for the clinical response to adalimumab, ustekinumab, secukinumab and ixekizumab